Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children by Liendo, Vera Lucia et al.
Original article 
211Arq Bras Oftalmol. 2017;80(4):211-4http://dx.doi.org/10.5935/0004-2749.20170052
INTRODUCTION
Ocular allergies constitute a heterogeneous group of frequently 
recurring inflammatory diseases of the ocular surface, with mani-
festations that range from mild to severe. Allergic conjunctivitis 
encompasses seasonal conjunctivitis, perennial conjunctivitis, atopic 
keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and 
giant papillary conjunctivitis(1). AKC and VKC are the most severe forms 
because of the possibility of visual impairment caused by corneal 
scarring, irregular astigmatism, cataract, and glaucoma(2,3). Glaucoma 
and cataract secondary to corticosteroid therapy are potential causes 
of blindness, which is a concern especially in young patients.
The treatment of ocular allergies involves a stepwise approach 
starting with preventative measures, such as avoidance of allergens, 
cold compress, and maintenance of a cool dry environment. Medical 
treatment, including preservative-free artificial tears, topical nonste-
roidal anti-inflammatory drugs, and topical antihistamines or mast 
cell stabilizers are used for milder cases. In contrast, more severe cases 
are treated with a combination of antihistamines or mast cell stabili-
zers and topical or systemic corticosteroids, which is given either as an 
intensive short-term therapy or as a long-term treatment regimen(4). 
The use of immunomodulators, such as cyclosporin A, is reserved for 
cases with steroid-dependent allergic keratoconjunctivitis or when 
the use of corticosteroids is contraindicated, for example in patients 
with advanced glaucoma(5). In severe cases refractory to medical 
treatment, surgical treatment, including excision of the tarsal pa-
pillae, superficial keratectomy with or without amniotic membrane 
graft, and eyelid surgery, may be performed.
Topical tacrolimus (TCL) is a potent immunosuppressive drug 
that is widely used to prevent allograft rejection of transplanted 
organs, such as the liver and kidneys(6). Its immunosuppressive effect 
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ABSTRACT
Purpose: Administration of eye drops containing antihistamines or sodium 
cromoglycate and its derivatives for the treatment of allergic keratoconjunctivitis 
is often insufficient and usually requires the addition of corticosteroids. However, 
the risk of complications, such as glaucoma and cataract, limits the use of 
corticosteroids to short courses, resulting in inadequate long-term treatment 
response. Immunosuppressive drugs have been considered as a valid alternative 
to steroids for atopic keratoconjunctivitis and vernal keratoconjunctivitis. This 
study aimed to evaluate the use of topical tacrolimus (TCL) in improving the 
clinical signs of severe allergic keratoconjuctivitis in children. 
Methods: Patients with severe allergic keratoconjunctivitis associated with cor-
neal epitheliopathy, gelatinous limbal infiltrates, and/or papillary reaction, along 
with a history of recurrences and resistance to conventional topical anti-allergy 
agents, were included in this open clinical trial. Patients were treated with 0.03% 
TCL ointment for ocular use. A severity score ranging from 0 to 9, with 9 being 
the highest and 0 being the lowest, was assigned based on signs observed on 
biomicroscopy prior to and following TCL treatment. 
Results: Analyses included 66 eyes of 33 patients. After a mean follow-up pe-
riod of 13 months (range, 12-29 months), TCL treatment significantly decreased 
the mean symptom score severity for the right (from 5.56 ± 1.18 to 2.76 ± 1.5; 
p<0.001) and left (from 5.94 ± 1.16 to 2.86 ± 1.64; p<0.001). 
Conclusion: Topical TCL was effective and significantly improved the clinical 
signs of allergic keratoconjuctivitis in children. Thus, it is a potential new option 
for severe and challenging cases of ocular allergy.
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RESUMO
Objetivos: O tratamento da ceratoconjuntivite alérgica baseado em colírios que 
contenham anti-histamínicos ou cromoglicato de sódio e seus derivados geralmente 
são insuficientes. A adição de corticosteróides geralmente é mandatória. No entanto, o 
risco de complicações como glaucoma e catarata limita o uso dos corticosteróides em 
curtos períodos de tratamento resultando em respostas inadequadas a longo prazo. 
Drogas imunossupressoras vem sendo consideradas como uma opção terapêutica 
alternativa válida para as ceratoconjuntivite atópica (AKC) e ceratoconjuntivite vernal 
(VKC). Este trabalho tem como objetivo avaliar a melhora nos sinais clínicos durante o 
uso de tacrolimus (TCL) tópico em crianças com ceratoconjuntivites alérgicas. 
Métodos: Pacientes com ceratoconjuntivite alérgica severa associada a ceratites, 
infiltrados limbares gelatinosos e/ou papilas gigantes, com história de recorrências 
e resistência ao tratamento anti-alérgico tópico convencional foram incluídos neste 
estudo. Os pacientes foram tratados com TCL 0,03% pomada tópica para uso ocular. 
Um escore variando de 0 a 9 foi atribuído para os sinais observados na biomicroscopia 
antes e depois do tratamento. Quanto maiores os escores, mais severos eram os sinais. 
Resultados: Foram estudados 66 olhos de 33 pacientes. Antes do tratamento a média 
do escore para o olho direito foi 5,56 ± 1,18 e para o olho esquerdo 5,94 ± 1,16. Após o 
tratamento com TCL a média do escore para o olho direito foi 2,76 ± 1,5 e para o olho 
esquerdo 2,86 ± 1,64 (p<0.001 para os dois olhos). O tempo de seguimento médio foi 
de 13 meses (12-29 meses). 
Conclusão: O presente estudo sugere que o TCL tópico foi efetivo e demonstrou 
resultado satisfatório, com melhora nos sinais clínicos na ceratoconjuntivite alérgica 
em crianças, constituindo uma nova opção para o tratamento de casos severos de 
alergia ocular.
Descritores: Córnea; Tacrolimo/uso terapêutico; Conjuntivite alérgica/quimioterapia
Topical Tacrolimus for The TreaTmenT of severe allergic keraToconjuncTiviTis in children
212 Arq Bras Oftalmol. 2017;80(4):211-4
is a result of the reduction in IL-2 production by T lymphocytes via a 
mechanism of action that is similar with that of cyclosporin. Moreo-
ver, previous studies reported that TCL as more potent and better 
tolerated than cyclosporine(7,8). Moreover, topical TCL has been des-
cribed to yield good results for AKC and other types of inflammatory 
diseases of the ocular surface(9). The other therapeutic indications for 
which TCL gave satisfactory results were inflammatory diseases, such 
as Mooren’s ulcer(10,11), high-risk penetrating keratoplasty(12), giant pa-
pillary conjunctivitis(13), AKC(14-16), VKC(17), and anterior uveitis(18). There 
are two concentrations of TCL ointment approved by the Food and 
Drug Administration (FDA) for the treatment of atopic dermatitis; 
these are the 0.1% preparation for use in patients over 16 years old 
and the 0.03% preparation for use in children over the age of 2 years. 
These reported benefits and few side effects of TCL, as well as the few 
available data in children, compelled us to carry out this work. The 
objective of the present study was to evaluate the use of topical TCL 
for the treatment of severe allergic keratoconjunctivitis in children.
METHODS
This prospective study evaluated the use of topical TCL in pa-
tients with severe ocular allergies. Patients who were on topical 
antiallergic treatment for severe allergic keratoconjunctivitis and 
who had suffered recent progression of signs and symptoms after 
discontinuation of topical corticosteroid therapy were included in 
the study. Allergic keratoconjunctivitis was defined as the presence 
of recurrent ocular surface inflammation characterized by keratitis, 
gelatinous limbal infiltration, and/or giant papillae on the tarsal 
conjunctiva. Patients under 7 years of age, those with diseases lea-
ding to scarring of the conjunctiva, those with infectious corneal 
ulcer, and those with a history of herpetic keratitis were excluded 
from the study. Patients who have undergone surgical excision of 
giant papillae on the tarsal conjunctiva and those who have used 
systemic immunosuppressors or supratarsal injection of corticoste-
roids within the previous 6 months were also excluded.
The use of a placebo control group in this trial was not allowed 
due to ethical considerations because it would have required some 
patients to receive nonuseful treatment. This design may have led to 
some bias in the estimation of treatment effect.
This study was undertaken at the Cornea and External Eye Disea-
se Clinic, Department of Ophthalmology, Federal University of São 
Paulo, Brazil from January 2009 to July 2011. It was approved by the 
institute’s internal review board under reference #1912-10. All indivi-
duals who participated in the study and/or their legal guardians gave 
a written informed consent for the study.
 The treatment protocol comprised application on both eyes of 
0.03% TCL ointment (Ophthalmos, São Paulo, Brazil) twice daily for at 
least 1 year, olopatadine hydrochloride 0.2% (Patanol S®) once daily, 
and an ocular lubricant containing polyethylene glycol (Oftane®) 
four times daily. All patients had been using olopatadine for at least 1 
month before the treatment regimen was started. Topical corticos-
teroid therapy was discontinued but was resumed for a few days 
and with fast tapering when exacerbations occurred and when the 
above-mentioned drugs were unable to control the allergic process.
At each visit, all patients underwent detailed ophthalmologic 
eva luation, including visual acuity, intraocular pressure measure-
ment, and slit-lamp biomicroscopic examination. Dilated fundus 
examination was performed on the first visit and was repeated as 
needed. The eyes were photographed for later comparison following 
TCL use.
Biomicroscopy included evaluation of the following items, in 
accor dance with the score system shown in chart 1: papillary reac-
tion, gelatinous limbal infiltrates, and corneal epitheliopathy. A score 
ranging from 0 to 9, with 9 being the highest and 0 being the lowest, 
was assigned to each eye prior to and following treatment to assess 
for any improvement in the patient’s clinical status (Figure 1). Classi-
fication was made in accordance with chart 1.
The patients were followed up at scheduled visits on days 1 and 
15 then monthly thereafter, except in cases that developed exacer-
bations occurred, in which case the patients were evaluated weekly. 
The final evaluation took place on July 2011.
Data were presented as frequencies and proportions or means 
and standard deviations. Wilcoxon test was used to compare the 
symptoms in the right and left eyes prior to and following TCL use. 
P-values <0.05 were considered statistically significant. The STATA 
software program, version 10 (College Station, Texas, USA), was used 
throughout the entire statistical analyzes. Data from each eye were 
analyzed separately to avoid the problem of rejecting useful data. 
Otherwise, the use of an overall summary of ocular findings for an 
individual may result in loss of relevant information and lead to less 
power and less precise estimates of effect, similar to when only one 
eye per individual is used.
RESULTS
The study included 33 patients, with a mean age of 12 ± 3.97 
years (range, 7-16 years): 23 (69.7%) were men and 10 (30.3%) were 
women. The mean duration of keratoconjunctivitis symptoms was 
5.8 ± 2.97 years (range, 1-15 years). VKC was diagnosed in 25 pa-
tients (75.76%), whereas AKC was seen in 8 patients (24.24%). Of the 
25 patients with VKC, 5 (20%) had the limbal form, 9 (36%) had the 
palpebral form, and 11 (44%) had the mixed form. The associated 
diseases present prior to starting TCL treatment were rhinitis in 24 
patients (72.73%), asthma in 14 (42.42%), dermatitis in 13 (39.39%), 
glaucoma in 6 (18.18%), and keratoconus in 4 (12.12%).
The mean follow-up duration was 13 months (range, 12-29 
months). Of the 33 patients, 20 cases (60.61%) had successfully con-
trolled disease and cessation of ocular allergy symptoms following 
TCL use, without recurrence of acute crisis (Figure 2). Recurrence 
was observed once in six patients (18.18%), twice in four patients 
(12.12%), and thrice in three patients (9.09%). As previously men-
tioned, short-course topical corticosteroids were administered as 
needed for some of these cases.
Four patients discontinued TCL because they developed irritation 
and burning sensation in the eyes. In one case, TCL was discontinued 
Chart 1. Classification of the signs observed at biomicroscopy. A score 
of 0-9 was assigned to each eye
Papillae
0: Micropapillae of the upper tarsal conjuctival and/or conjuctival thickening
1: Prominent papilary reaction in the upper/lower tarsal conjuctuva with thickening, 
hampering observation of the vascular pattern.
2: Thickened conjuctival surface with many papillae (some giant) on the upper 
tarsal conjuctiva, preventing observation of the vascular pattern and/or fibrosis.
3: Predominance of giant papillae on the upper tarsal conjuctiva.
Gelationous limbal infiltrates
0: Normal limbus.
1: Mild hyperemia an edema
2: As above, together with the presence of Horner-Trantas dots in 1-2 quadrants.
3: As above, together with the presence of Horner-Trantas dots in more than 2 
quadrants.
Keratitis
0: Absent
1: Punctante epithelial
2: Coarse puctante ephitelial keratitis and/or focal or diffuse or epithelial erosion
3: Epithelial defect or shield ulcer
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due to the appearance of ocular herpes (dendritic epithelial kerati-
tis) following initiation of treatment; this patient was treated with 
topical antiviral medication for 10 days until complete resolution of 
the clinical condition. These five patients were excluded from the 
statistical analyzes.
Following TCL use, there were no reports of intraocular inflamma-
tion, glaucoma, increase of ocular pressure, and cataract.
DISCUSSION
The treatment of severe allergic keratoconjunctivitis involves 
cor ticosteroid eye drops in addition to topical antiallergic drugs and 
artificial tears. However, due to the possible side effects such as 
cataract and glaucoma, corticosteroid-sparing drugs are frequently 
needed(4). Topical immunomodulators, such as TCL and cyclosporine, 
are safe alternatives for long-term treatment of these patients, with 
side effects that are generally transient and without rebound effects 
following discontinuation of the drug(13).
The effect of topical cyclosporine depends on its concentration, 
which ranges from 0.05% to 2%; the higher the concentration, the po-
orer the tolerability and compliance with the treatment, particularly 
in young patients(19-21). Daniell et al. showed that topical 0.05% cyclos-
porin failed to control VKC and AKC in steroid-dependent patients(16). 
In another study conducted on patients with VKC, topical cyclosporin 
at 1% and 2% was proven to be effective for a long-term control of 
the allergy(17). A systematic review suggested that topical cyclosporin 
may provide clinical and symptomatic relief from AKC and may help 
reduce topical steroid use in patients with steroid-dependent AKC(22).
In the present study, TCL was chosen for the treatment of seve-
re allergic keratoconjunctivitis because of the poor tolerability to 
cyclosporine,ambiguous results, and of little experience with TCL at 
the beginning of the clinical trial. Following the use of topical TCL 
0.03% for severe cases of allergic keratoconjunctivitis in children, 
there were significant improvements in clinical signs of corneal epi-
theliopathy, limbal involvement, and papillary reaction; this reduced 
the need for topical corticoids and the associated side effects.
Labcharoenwongs et al. published a clinical trial comparing 
topical TCL and cyclosporine for VKC; twice daily use of TCL ophthal-
mic ointment tended to be more effective than cyclosporine in im-
proving the ocular signs(23). Systemic TCL, which is used to prevent 
organ rejection in individuals subjected to heart, lung, liver, kidney, 
pancreas, bowel, or bone marrow transplant, was reported to be 
10-100 times more powerful than cyclosporine(13). In an in vitro 
study, the immunosuppressive effect of TCL was found to be up 
to 100 times more potent than that of cyclosporine(18). Topical TCL 
ointment and pimecrolimus cream have been commercially availa-
ble for more than a decade and are the first and only drugs appro-
ved for chronic treatment of atopic dermatitis in pediatric patients 
because these are not associated with skin barrier compromise or 
increased percutaneous absorption. TCL at concentrations of 0.1% 
and 0.03% is currently available on the market for use in dermato-
logy, with ex cellent results in atopic dermatitis(24).
A study conducted on patients treated with topical TCL evalua-
ted cytology samples of the conjunctiva and found a statistically 
significant reduction in the number of eosinophils, neutrophils, 
and squamous metaplasia; no cases of cellular atypia were found(25). 
According to Attas-Fox et al., the blood level of TCL following topical 
use is negligible(26). Ohashi et al. reported that the use of topical 
TCL 0.1% for the treatment of allergic conjunctivitis was effective in 
improving the symptoms, in decreasing the size of the giant papillae 
on the tarsal conjunctiva, and in addressing corneal involvement(27). 
Tzu et al. evaluated the long-term effectiveness of the combination 
of topical cyclosporine drops and TCL ointment in the treatment of 
steroid-dependent AKC; there was improvement of the symptoms 
and signs, and the number of flare-up episodes requiring topical 
steroids was low(28).
 The side effects of ocular use of TCL are generally tolerable, and 
only a few have reported the need to discontinue treatment(9). There 
have been no reports on increase in intraocular pressure associa-
ted with the use of topical TCL; therefore, this drug appears to be 
a good option for patients with glaucoma or history of increased 
intraocular pressure following the use of topical corticosteroids, as 
well as for those with cataracts induced by corticosteroids(29). Only 
4 of the 33 patients in this study were unable to continue the use 
of TCL due to irritation and burning in their eyes. There are no data 
in literature describing the cause of TCL intolerance, as has been 
reported for cyclosporine(19).
In patients given this immunosuppressive therapy with TCL, the 
risk for potential adverse effects, including reactivation of herpes and 
malignancy, should be taken into consideration. Development of 
cutaneous herpes simplex after application of topical TCL for atopic 
dermatitis was reported in one study(30). In the present study, only one 
patient had an episode of ocular herpes after initiation TCL treatment. 
Although the use of topical calcineurin inhibitors, such as TCL, has 
Figure 1. Clinical scores before and after tacrolimus ointment treatment for patients 
with allergic keratoconjunctivitis (n=66 eyes), mean follow-up duration was 13 months 
(range, 12-29 months).
Figure 2. Pretreatment (A and B) and post treatment (C and D) with topical tacrolimus 
in a patient with vernal keratoconjunctivitis. Note the improvement in the papillae and 
keratitis after the treatment (C and D).
A
B D
C
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been reported to have a theoretical risk for malignancy, including 
lymphoma, analyzes of epidemiologic and clinical data failed to 
demonstrate a causal relationship between TCI use and malignancy 
or lymphoma risk. Despite this potential risk, these drugs are consi-
dered safe and remain to be the only approved long-term treatment 
medication for children 2 years and older with atopic dermatitis(31).
 The present study suggested that topical TCL was effective and 
rendered satisfactory results, specifically significant improvements in 
the clinical signs of allergic keratoconjuctivitis, in children; it might 
be a new option for severe and challenging cases of ocular allergy. A 
longer follow-up time is required to evaluate the long-term reprodu-
cibility of these results. The absence of a control group for compari-
son with patients who received standard treatment for ocular allergy 
and the difference in treatment duration among patients may have 
led to some bias in the estimation of treatment effect.
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